Momenta says Pfizer, a key supplier for its multiple sclerosis drug, has received a warning letter from the Food and Drug Administration. » Read More
By: Clay Dillow, special to CNBC.com
Recursion Pharmaceuticals is using robots to find treatments for rare diseases like sickle cell anemia and cystic fibrosis. » Read More
By: Justina Crabtree
While the development of contraceptives aimed at men is gaining ground, interest from big pharma just isn't there, according to one expert. » Read More
Merck Group CEO Stefan Oschmann discusses his outlook for 2017 and how big data is transforming the pharmaceuticals industry.
Novartis CEO Joe Jimenez discusses investment in the United States under U.S. President-elect Donald Trump.
Merck Group CEO Stefan Oschmann speaks about how his world has changed after Donald Trump's election.
Novartis CEO Joe Jimenez discusses how his sector may develop under Donald Trump's presidency.
Steve Brozak at WBB Securities explains why he favors Omeros stocks.
The lack of clarity over Trump’s policies was so great that fund manager Invesco is reducing risk exposure, a senior portfolio manager said.
The new CMS classification means the device is eligible for Medicaid and Medicare coverage.
It's becoming obvious Big Pharma's iron wall of protection in Washington is starting to crumble, says Jake Novak.
Price and Rep. Chris Collins, R-N.Y., got a 12 percent discount in their private placement purchase of stock in an Australian drug company.
"Sugar Goggles," a virtual reality game, is hoping to encourage children to make healthier eating choices and adjust eating habits.
When someone goes into opioid overdose, their body begins shutting down. But there’s a drug that can stop the process. Naloxone has saved the thousands of people after they overdosed. Here’s how it works.
Investor optimism regarding the outlook for European healthcare stocks continued to decline dramatically on Thursday.
Morgan Stanley's 2020 earnings-per-share estimate for Merck is $5.82 versus the Wall Street consensus of $4.97.
Andrew Keene at KeeneOnTheMarket.com says that Trump is still better for pharmaceutical stocks than Clinton would have been.
Shkreli, who is accused of securities fraud, is free on $5 million bail, and normally must stay in New York.
Chris Meekins, FBR Capital Markets research analyst, and Seamus Fernandez, Leerink Partners managing director & pharma analyst, discuss President-elect Trump's comments on drug pricing and their effect on biotech and pharma stocks.
CNBC's Bob Pisani and Art Cashin, of UBS, discuss the market’s reaction to President-elect Donald Trump’s first news conference since Election Day.
Trump's Obamacare remarks came at a news conference that was his first since being elected president of the United States.
On Wednesday, President-elect Donald Trump held his first news conference since his election in November.
The "Squawk on the Street" crew discuss the new leadership group in the markets: biotech stocks.
Get the best of CNBC in your inbox